A citation-based method for searching scientific literature

Shang-Gin Wu, Yao-Wen Kuo, Yih-Leong Chang, Jin-Yuan Shih, Ya-Hui Chen, Meng-Feng Tsai, Chong-Jen Yu, Chih-Hsin Yang, Pan-Chyr Yang. J Thorac Oncol 2012
Times Cited: 78







List of co-cited articles
539 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
58

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
53

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
43

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Scott J Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y Yeap, Alice Shaw, Justine A Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark,[...]. Clin Cancer Res 2009
480
37

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Daisy Wing-Sze Wong, Elaine Lai-Han Leung, Kimpton Kam-Ting So, Issan Yee-San Tam, Alan Dart-Loon Sihoe, Lik-Cheung Cheng, Kwok-Keung Ho, Joseph Siu-Kie Au, Lap-Ping Chung, Maria Pik Wong. Cancer 2009
532
33

Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
Ping Yang, Kimary Kulig, Jennifer M Boland, Michele R Erickson-Johnson, Andre M Oliveira, Jason Wampfler, Aminah Jatoi, Claude Deschamps, Randolph Marks, Connie Fortner,[...]. J Thorac Oncol 2012
98
30

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
Xuchao Zhang, Shirley Zhang, Xuening Yang, Jinji Yang, Qing Zhou, Lucy Yin, Shejuan An, Jiaying Lin, Shiliang Chen, Zhi Xie,[...]. Mol Cancer 2010
231
28

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Jussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison J Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Roman Thomas,[...]. Clin Cancer Res 2008
705
26

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
25

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
24

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
D Ross Camidge, Scott A Kono, Xian Lu, Sonia Okuyama, Anna E Barón, Ana B Oton, Angela M Davies, Marileila Varella-Garcia, Wilbur Franklin, Robert C Doebele. J Thorac Oncol 2011
180
23

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney,[...]. Lancet Oncol 2011
675
23

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
Kengo Takeuchi, Young Lim Choi, Yuki Togashi, Manabu Soda, Satoko Hatano, Kentaro Inamura, Shuji Takada, Toshihide Ueno, Yoshihiro Yamashita, Yukitoshi Satoh,[...]. Clin Cancer Res 2009
518
23

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Kimie Nomura, Hironori Ninomiya, Michiyo Okui, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Manabu Soda,[...]. J Thorac Oncol 2008
341
21

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
21

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
June Koo Lee, Heae Surng Park, Dong-Wan Kim, Kimary Kulig, Tae Min Kim, Se-Hoon Lee, Yoon-Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo-Ho Kim,[...]. Cancer 2012
39
38

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Jin Ho Paik, Chang-Min Choi, Hyojin Kim, Se Jin Jang, Gheeyoung Choe, Dong Kwan Kim, Hwa Jung Kim, Hoil Yoon, Choon-Taek Lee, Sanghoon Jheon,[...]. Lung Cancer 2012
124
19

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
17

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
17

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Soyeon Kim, Yoon-Kyung Jeon, Doo Hyun Chung, Woo-Ho Kim, Young Tae Kim, Seok-Chul Yang,[...]. J Thorac Oncol 2011
125
16

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
16

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
Maria Paola Martelli, Gabriella Sozzi, Luis Hernandez, Valentina Pettirossi, Alba Navarro, Davide Conte, Patrizia Gasparini, Federica Perrone, Piergiorgio Modena, Ugo Pastorino,[...]. Am J Pathol 2009
243
16

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Hye Ryun Kim, Hyo Sup Shim, Jin-Haeng Chung, Young Joo Lee, Yun Kyoung Hong, Sun Young Rha, Se Hoon Kim, Sang-Jun Ha, Se Kyu Kim, Kyung Young Chung,[...]. Cancer 2012
106
16

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher Lathan, J Paul Marcoux, Jinyan Du, Katsuhiro Okuda,[...]. Cancer Res 2011
435
15

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
15

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
988
15

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.
Yuki Togashi, Manabu Soda, Seiji Sakata, Emiko Sugawara, Satoko Hatano, Reimi Asaka, Takashi Nakajima, Hiroyuki Mano, Kengo Takeuchi. PLoS One 2012
170
15

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Satoko Hatano, Hironori Ninomiya, Noriko Motoi, Ming-yon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa,[...]. Mod Pathol 2009
326
14

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Kengo Takeuchi, Young Lim Choi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Yukitoshi Satoh,[...]. Clin Cancer Res 2008
368
14

A mouse model for EML4-ALK-positive lung cancer.
Manabu Soda, Shuji Takada, Kengo Takeuchi, Young Lim Choi, Munehiro Enomoto, Toshihide Ueno, Hidenori Haruta, Toru Hamada, Yoshihiro Yamashita, Yuichi Ishikawa,[...]. Proc Natl Acad Sci U S A 2008
378
14

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L Sos, Mirjam Koker, Lydia Meder, Christine M Lovly, Lukas C Heukamp, William Pao,[...]. Clin Cancer Res 2012
180
14

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
891
14

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
840
12

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
Eunhee S Yi, Jennifer M Boland, Joseph J Maleszewski, Anja C Roden, Andre M Oliveira, Marie-Christine Aubry, Michele R Erickson-Johnson, Bolette L Caron, Yan Li, Hui Tang,[...]. J Thorac Oncol 2011
219
12

Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
Youngil Koh, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Yoon Kyung Jeon, Doo Hyun Chung, Young-Whan Kim, Dae Seog Heo, Woo-Ho Kim, Yung-Jue Bang. J Thorac Oncol 2011
49
20

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
Mari Mino-Kenudson, Lucian R Chirieac, Kenny Law, Jason L Hornick, Neal Lindeman, Eugene J Mark, David W Cohen, Bruce E Johnson, Pasi A Jänne, A John Iafrate,[...]. Clin Cancer Res 2010
340
12

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
12

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Tsuyoshi Takahashi, Makoto Sonobe, Masashi Kobayashi, Akihiko Yoshizawa, Toshi Menju, Ei Nakayama, Nobuya Mino, Shotaro Iwakiri, Kiyoshi Sato, Ryo Miyahara,[...]. Ann Surg Oncol 2010
252
12

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
361
12

Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
Takayuki Fukui, Yasushi Yatabe, Yoshihisa Kobayashi, Kenji Tomizawa, Simon Ito, Shunzo Hatooka, Keitaro Matsuo, Tetsuya Mitsudomi. Lung Cancer 2012
87
12

Ceritinib in ALK-rearranged non-small-cell lung cancer.
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, Enriqueta Felip, Laura Q M Chow, D Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas,[...]. N Engl J Med 2014
998
12

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Robert C Doebele, Xian Lu, Christopher Sumey, Delee A Maxson, Andrew J Weickhardt, Ana B Oton, Paul A Bunn, Anna E Barón, Wilbur A Franklin, Dara L Aisner,[...]. Cancer 2012
189
11

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
11

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Robert C Doebele, Amanda B Pilling, Dara L Aisner, Tatiana G Kutateladze, Anh T Le, Andrew J Weickhardt, Kimi L Kondo, Derek J Linderman, Lynn E Heasley, Wilbur A Franklin,[...]. Clin Cancer Res 2012
765
11

Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Akihiko Yoshida, Koji Tsuta, Harumi Nakamura, Takashi Kohno, Fumiaki Takahashi, Hisao Asamura, Ikuo Sekine, Masashi Fukayama, Tatsuhiro Shibata, Koh Furuta,[...]. Am J Surg Pathol 2011
208
11

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.
Anne McLeer-Florin, Denis Moro-Sibilot, Adrien Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Elisabeth Brambilla, Sylvie Lantuejoul. J Thorac Oncol 2012
158
11

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Jennifer M Boland, Sibel Erdogan, George Vasmatzis, Ping Yang, Lori S Tillmans, Michele R Erickson Johnson, Xiaoke Wang, Lisa M Peterson, Kevin C Halling, Andre M Oliveira,[...]. Hum Pathol 2009
133
11

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
11

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Young Lim Choi, Kengo Takeuchi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Toru Hamada, Hidenori Haruta, Hideki Watanabe,[...]. Cancer Res 2008
324
11

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Ryohei Katayama, Tahsin M Khan, Cyril Benes, Eugene Lifshits, Hiromichi Ebi, Victor M Rivera, William C Shakespeare, A John Iafrate, Jeffrey A Engelman, Alice T Shaw. Proc Natl Acad Sci U S A 2011
399
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.